Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 20/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20589033 | 1.00 | HPGDS (0.75) | HPGDS | |
| SCHEMBL20589230 | 0.86 | HPGDS (1.00) | HPGDS | |
| SCHEMBL21945761 | 0.86 | HPGDS (1.00) | HPGDS | |
| SCHEMBL21853644 | 0.86 | HPGDS (1.00) | HPGDS | |
| SCHEMBL21945686 | 0.84 | HPGDS (0.77) | HPGDS | |
| SCHEMBL20588980 | 0.82 | HPGDS (0.76) | HPGDS | |
| SCHEMBL21853609 | 0.82 | HPGDS (0.76) | HPGDS | |
| SCHEMBL20588218 | 0.81 | HPGDS (0.82) | HPGDS | |
| SCHEMBL21853640 | 0.81 | HPGDS (0.82) | HPGDS | |
| SCHEMBL20589080 | 0.81 | HPGDS (0.78) | HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149035-B2 | Chemical compounds as H—PGDS inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DFVELOPMENT LIMITED (GB) | 2021-10-19 | — | — | US | claimed |
| US-20200123152-A1 | Chemical Compounds as H-PGDS Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-04-23 | — | — | US | claimed |
| CN-110753692-A | Chemical compounds as H-PGDS inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-02-04 | — | — | CN | claimed |
| US-11149035-B2 | Chemical compounds as H—PGDS inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DFVELOPMENT LIMITED (GB) | 2021-10-19 | — | — | US | disclosed |
| US-20200123152-A1 | Chemical Compounds as H-PGDS Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-04-23 | — | — | US | disclosed |
| CN-110753692-A | Chemical compounds as H-PGDS inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-02-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149035-B2 | Chemical compounds as H—PGDS inhibitors | HPGDS, PTGS1, PTGIS | HPGDS 1/4885 |
| US-20200123152-A1 | Chemical Compounds as H-PGDS Inhibitors | HPGDS, PTGS1, PTGIS | HPGDS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.